Anti-Nectin-4 MMAE Conjugate Formulation for Low Shedding Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugate formulations face challenges in maintaining stability and preventing the formation of aggregates and degradation products, which can lead to immunogenicity and venous disorders, and there is a need for a stable formulation suitable for antibody-drug conjugates, particularly for those targeting Nectin-4 overexpressing cancers.
Innovation Solution
A recombinant humanized anti-Nectin-4 monoclonal antibody-MMAE drug conjugate is developed with site-specific modification using microbial transglutaminase, optimized with a specific drug-linker structure and formulated with histidine-histidine hydrochloride buffer, polysorbate 20, trehalose, and pH 5.0-6.5 to minimize shedding and ensure stability, further processed into a lyophilized powder for long-term storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If antibody-drug conjugate is formulated in aqueous injection form, then ease of administration is improved, but stability and aggregation formation worsen
Solution Approach 1:
The patent employs lyophilization (freeze-drying) to transform the antibody-drug conjugate from liquid aqueous form to solid powder form. This phase transition removes water that causes aggregation and degradation, significantly improving formulation stability while maintaining ease of administration through reconstitution before injection
Solution Approach 2:
The patent optimizes formulation parameters including pH (adjusted to 5.0-6.5 using acetate buffer), temperature (storage at 2-8°C), and composition (adding stabilizers like trehalose and surfactants like polysorbate 80). These parameter changes prevent aggregation and degradation, resolving the stability issue while maintaining administrability
2Ease of operation
If antibody-drug conjugate is stored at room temperature, then ease of storage is improved, but product homogeneity and stability worsen
Solution Approach 1:
Lyophilization transforms the product into a solid powder state that is inherently more stable and less susceptible to temperature-induced degradation and aggregation. The removed water prevents hydrolysis and microbial growth, allowing stable storage at 2-8°C with maintained homogeneity
Solution Approach 2:
The formulation includes pre-added stabilizers (trehalose, polysorbate 80) and pH buffers that proactively protect the antibody-drug conjugate from degradation during storage. This preliminary protection maintains product homogeneity without requiring complex temperature control
3Reliability
If drug-linker moiety is used for targeted delivery, then therapeutic efficacy is improved, but drug shedding and toxicity worsen
Solution Approach 1:
The patent uses a specially designed linker (containing Val-Cit dipeptide and pABC) as an intermediary between the antibody and MMAE drug. This linker provides stable conjugation during circulation (preventing shedding) while enabling controlled drug release through protease cleavage in the tumor microenvironment (maintaining efficacy)
Solution Approach 2:
The drug-linker conjugation is designed with site-specificity, attaching the drug at particular locations on the antibody molecule. This local quality control ensures uniform distribution and stable bonding, reducing drug shedding while maintaining targeted delivery efficacy
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A pharmaceutical composition, comprising (i) an antibody-drug conjugate, (ii) a histidine buffer, (iii) trehalose, and (iv) a surfactant; and a method for preparing the pharmaceutical composition.